23 May 2013
Keywords: merck, cordaptive, positive, impact, key, lipid, parameters
Article | 10 September 2007
US drugmaker Merck & Co says that results from a Phase III trial of Cordaptive (extended-release niacin/laropiprant) show that the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 September 2007
17 September 2007
22 May 2013
© 2013 thepharmaletter.com